In two recent articles,Baruch et al.1 and Davar et al.2 bring up the first proof-of-concept that fecal microbiota transplantation(FMT)transfer clinical benefit in metastatic melanoma patients primarily resistant to im...In two recent articles,Baruch et al.1 and Davar et al.2 bring up the first proof-of-concept that fecal microbiota transplantation(FMT)transfer clinical benefit in metastatic melanoma patients primarily resistant to immune checkpoint blockade(ICB).FMT shifted the microbiota of recipients toward a donor-type taxonomic composition associated with immune activation,anti-inflammatory tonus,and changes in the host metabolism.展开更多
文摘In two recent articles,Baruch et al.1 and Davar et al.2 bring up the first proof-of-concept that fecal microbiota transplantation(FMT)transfer clinical benefit in metastatic melanoma patients primarily resistant to immune checkpoint blockade(ICB).FMT shifted the microbiota of recipients toward a donor-type taxonomic composition associated with immune activation,anti-inflammatory tonus,and changes in the host metabolism.
